International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

IF 0.1 Q4 ONCOLOGY

Onkourologiya Pub Date : 2021-02-10 DOI:10.17650/1726-9776-2020-16-4-197-206

V. Matveev, O. Khalmurzaev, O. Evsyukova

引用次数: 1

Abstract

The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.

查看原文本刊更多论文

奥拉帕尼治疗转移性去势抵抗性前列腺癌的国际经验:文献综述

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Onkourologiya ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.